SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
1. Sarepta faces a class action lawsuit over ELEVIDYS safety issues. 2. Two patient deaths have raised regulatory scrutiny and halted clinical trials. 3. Stock price has significantly declined following safety updates and regulatory news.